Key Highlights

  • CDT Equity Penny Stock shares fell 33.88% to $0.08 at last closing, extending a decline that began the prior session, after announcing a 1-for-25 reverse stock split.
  • The split takes effect at 5:00 p.m. ET on September 28, with split-adjusted trading beginning September 29 under the same CDT ticker.
  • This is the company's fourth reverse split in about 18 months, following splits of 1-for-100, 1-for-15, and 1-for-10, with the latest coming barely ten weeks after the last.
  • About 1,124,515 shares will be outstanding after the split, implying roughly 28 million shares were outstanding beforehand, nearly double the company's late-August count.

CDT Equity Inc. Penny Stock (NASDAQ:CDT), a small biopharmaceutical development company, sold off heavily after the board approved a 1-for-25 Reverse Stock Split to ensure continued compliance with Nasdaq's bid-price rule, which requires a Listed Stock to trade at or above $1.00. The stock never recovered during the session, extending a decline that had already started a day earlier.

Under the split, every 25 existing shares become one new share, effective 5:00 p.m. ET on Monday, September 28, 2026, with split-adjusted trading starting at the open the next day under the same CDT ticker on the Nasdaq Capital Market. Holders who would end up with part of a share will get cash instead, based on the September 28 closing price, and equity awards, convertible securities and warrants will be adjusted proportionally.

Latest Developments

A reverse split does not change what a company is worth on paper, but the reason for the split matters more than the mechanics: a company does this when its share price has sunk toward or below $1, which usually reflects repeated share issuance and weak investor demand, so the announcement confirms that problem rather than solving it. CDT's history makes this one stand out, since the company, formerly known as Conduit Pharmaceuticals, carried out a 1-for-100 reverse split in January 2025, a 1-for-15 split in May 2025, and a 1-for-10 split effective July 17, 2026, also citing the bid-price rule.

The share count has also been climbing fast: on September 2, CDT said it had 13,693,866 shares outstanding as of August 31 with no remaining Nasdaq deficiencies, crediting recent share issuances and Warrant exercises. The post-split figure of about 1.12 million implies roughly 28 million shares were outstanding before this split, about double the late-August count, though the company has not explained the increase in its recent disclosures.

Financial and Business Position

CDT Equity describes itself as a data-driven biopharmaceutical development company that aims to find, enhance and advance drug candidates, leaning on artificial intelligence and solid-form chemistry, creating value through licensing, acquisitions and partnerships rather than a large in-house development operation. Recent activity includes a September Partnership with QIMA Life Sciences to evaluate tapinarof combinations for psoriasis and vitiligo, a stake of about 22.7% in Sarborg Limited, an AI and Quantum Computing company, and an August Investment in peptide company Pep'd through a SAFE note.

The company reported stockholders' equity of roughly $103 million in its June 30 quarterly report, well above the approximately $23 million market Capitalization it cited at the time, a gap that suggests investors put a low value on its assets. Co-founder James Bligh became chief executive on September 1, while predecessor Andrew Regan moved to lead Sarborg.

Stock-Market Context

Under Nasdaq rules approved in 2025, a company that falls below $1 within a year of a reverse split no longer gets the usual 180-day grace period to fix it, instead facing a delisting determination it can appeal to a hearings panel, with serial splits counting against a company over a two-year window, leaving CDT with little room for error if shares slide again after this split.

Little Margin Left Under the New Delisting Rules

Investors are watching whether the split-adjusted price holds comfortably above $1 when trading begins September 29, any further stock sales, warrant exercises or financing disclosures that would show whether dilution continues at the same pace, potential new Nasdaq notices that could go straight to a delisting determination given the one-year lookback rule, and progress on the tapinarof partnership, the Sarborg stake, or other licensing deals that could shift sentiment.